Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.69 |
| ▸ | GRM5 | P41594 | 10/20 | 0.62 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31150581 | 0.90 | PDK4 (0.67) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL21855632 | 0.90 | PDK4 (0.67) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL19284578 | 0.89 | PDK4 (0.65) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL12712612 | 0.87 | PDK4 (0.69) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL19284673 | 0.86 | PDK4 (0.62) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL3642397 | 0.86 | PDK4 (0.68) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL17268510 | 0.86 | PDK4 (0.68) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL30061046 | 0.86 | PDK4 (0.68) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL2882861 | 0.86 | PDK4 (0.68) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL30135250 | 0.86 | PDK4 (0.68) | PDK4GRM5GRM1HTR6NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970272-A1 | GLYCOSIDASE INHIBITORS | Merck Patent GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| CN-105143222-A | Glycosidase inhibitors | MERCK PATENT GMBH | 2015-12-09 | — | — | CN | disclosed |
| WO-2014159234-A1 | GLYCOSIDASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159234-A1 | GLYCOSIDASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031871-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | PDK4 2751/4885GRM5 750/4885GRM1 451/4885 |
| US-10301299-B2 | Glycosidase inhibitors | GAA, BACE1, GBA3 | PDK4 2751/4885GRM5 750/4885GRM1 451/4885 |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | PDK4 1189/4885GRM5 1092/4885GRM1 2182/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | PDK4 1189/4885GRM5 1092/4885GRM1 2182/4885 |
| US-20180093977-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | PDK4 2751/4885GRM5 750/4885GRM1 451/4885 |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | PDK4 1001/4885GRM5 1055/4885GRM1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.